Hormonal
GIPR (Gastric Inhibitory Polypeptide Receptor) is expressed in human hypothalamic ependymal cells surrounding the third ventricle, suggesting a potential mechanism for how GIPR-targeting drugs like tirzepatide access the brain.
This research suggests that drugs targeting the GIP receptor (like tirzepatide) may interact with cells lining the fluid spaces in your brain. This provides a biological basis for how these medications might influence brain function related to appetite, beyond just their effects on the stomach.
we detected GIPR expression in... strikingly, the ependymal cells (C4-94) surrounding the 3rd ventricle... Could these GIPR expressing cells be increasing access of tirzepatide to the hypothalamus?
Why this rating
High-resolution spatial mapping confirms the location, but functional validation of drug access is not yet performed.
Source
Human HYPOMAP: A comprehensive spatio-cellular map of the human hypothalamus
John A. Tadross et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2023
DOI 10.1101/2023.09.15.557967
More from this paper
- GLP1R-expressing neurons in the human hypothalamus, specifically those co-expressing POMC in the arcuate nucleus and AVP in the paraventricular/supraoptic nuclei, are the primary neural targets mediating the appetite-suppressing effects of GLP-1 receptor agonists like semaglutide.Good
- Rare deleterious variants in the gene CORO1A are significantly associated with changes in BMI at the population level, identifying it as a novel genetic factor in obesity risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →